Health Care https://www.benzinga.com/views/taxonomy/term/140295 en Mental Health Watchdog, CCHR Florida, Fights Baker Act Abuses https://www.benzinga.com/pressreleases/18/06/g11916521/mental-health-watchdog-cchr-florida-fights-baker-act-abuses <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">CLEARWATER Fla., June 21, 2018 (GLOBE NEWSWIRE) -- The Florida chapter of the Citizens Commission on Human Rights (CCHR), a mental health watchdog organization co-founded by the Church of Scientology and psychiatrist Dr. Thomas Szasz in 1969, announced that in 2017 they helped secure the safe release of some 300 people being unjustly held for involuntary psychiatric examination.  CCHR Florida maintains a hotline for Baker Act abuses.<br /></p> <p align="left">"Every day in Florida someone is held for involuntary psychiatric examination [Baker Act] for the scantiest of reasons," said Stephen A. Talmadge, PhD and a Diplomate of the American Board of Forensic Psychology.</p> <p align="left">The Baker Act mental health law allows Florida citizens, including children, to be sent against their will for involuntary examination at psychiatric wards known as Baker Act Receiving Facilities and held for up ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11916521/mental-health-watchdog-cchr-florida-fights-baker-act-abuses alt=Mental Health Watchdog, CCHR Florida, Fights Baker Act Abuses>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 21 Jun 2018 17:40:35 +0000 Globe Newswire 11916521 at https://www.benzinga.com VITAS HEALTHCARE TO ATTEND AHIP INSTITUTE & EXPO 2018 https://www.benzinga.com/pressreleases/18/06/g11916384/vitas-healthcare-to-attend-ahip-institute-expo-2018 <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Miami, FL, June 21, 2018 (GLOBE NEWSWIRE) -- VITAS Healthcare, the nation&#039;s leading provider of end-of-life care, is attending the America&#039;s Health Insurance Plans (AHIP) Institute &amp; Expo 2018, being held June 20-22 in San Diego, CA.<br /><br />VITAS&#039; presence at AHIP focuses on showcasing its seamless <a href="https://www.globenewswire.com/Tracker?data=sfWGB0aIfLB45555O_kZiS1v6YuLZSvvL_0abiBUsS4yt2AyBlDC1GKtBVo_aGDumnJSd4p19BE8_stslv8tr7KwmjuKyKMNArXFnyIqmD7O9i4agW-wiocw_isEPHzBS8lgzI72HXwpO27AEWgDg6MgPXl0F3R-zyNvBGjJRmU=" rel="nofollow" target="_blank" rel="nofollow">care transitions for hospice patients</a> to healthcare providers who wish to add an additional value to their health plans. With extensive experience in projecting disease trajectories, dealing with multiple disease states and expertise in mortality pathways, VITAS shows the value hospice can bring by educating providers in these areas.<br /><br />"The deep expertise VITAS brings to insurance plans not only provides patients with exceptional, high-quality care but reduces overall healthcare costs," said Dr. Joseph Shega, senior vice president and chief medical officer for VITAS. "We look forward to sharing the value hospice can bring to providers and hearing ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11916384/vitas-healthcare-to-attend-ahip-institute-expo-2018 alt=VITAS HEALTHCARE TO ATTEND AHIP INSTITUTE &amp; EXPO 2018>Full story available on Benzinga.com</a></p> CHE Health Care Press Releases CHE US16359R1032 Health Care Press Releases Benzinga Thu, 21 Jun 2018 17:13:55 +0000 Globe Newswire 11916384 at https://www.benzinga.com 8 Children Unintentionally Killed or Injured by Guns in U.S. Every Day https://www.benzinga.com/pressreleases/18/06/g11916342/8-children-unintentionally-killed-or-injured-by-guns-in-u-s-every-day <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Washington, D.C., June 21, 2018 (GLOBE NEWSWIRE) -- As schools let out across the country on the first day of summer, parents are taking steps to keep their children safer from unintentional gun violence. The Brady Center to Prevent Gun Violence joined with child safety and public health organizations nationwide today to promote ASK (Asking Saves Kids) Day, a campaign encouraging parents to ASK if there is an unlocked gun in the homes where their children play.</p> <table border="0"> <tr> <td> <table width="293" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/01e01419-ee43-4238-8dff-164657456626/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/01e01419-ee43-4238-8dff-164657456626?size=2" border="0" width="288" height="131" alt="0_int_BradyCenterLogo.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p> <br /> </p> <p>Kris Brown, co-president of the Brady Center, stated:</p> <p> <br /> </p> <p>"As a mother of two daughters, I know the role of caregivers in asking critical, life saving questions related to our children&#039;s safety. Asking about guns in the home must be one of the questions routinely asked. I&#039;ve heard too many stories of children lost to family fire in the home not to ask. ASK Day is an important opportunity for parents to take a simple step to protect their kids by making sure they aren&#039;t playing in homes with unsecured guns. Just by asking, a parent can make all the ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11916342/8-children-unintentionally-killed-or-injured-by-guns-in-u-s-every-day alt=8 Children Unintentionally Killed or Injured by Guns in U.S. Every Day>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 21 Jun 2018 17:03:51 +0000 Globe Newswire 11916342 at https://www.benzinga.com Kyle Fisher named Chief Financial Officer for Community Health Network https://www.benzinga.com/pressreleases/18/06/g11916112/kyle-fisher-named-chief-financial-officer-for-community-health-network <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Indianapolis, June 21, 2018 (GLOBE NEWSWIRE) -- Community Health Network announced Kyle Fisher, its former chief retail and innovation officer and chief executive officer for Visionary Enterprises, Inc. (VEI), has been named the network&#039;s chief financial officer. The move became effective June 18. </p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/f5902c67-e640-4f7a-a080-f4f94f0be1a0/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/f5902c67-e640-4f7a-a080-f4f94f0be1a0?size=2" border="0" width="300" height="300" alt="0_int_Kyle-Fisher_0.jpg" /></a></td> </tr> <tr> <td class="gnw_media_caption" width="5"></td> <td align="left" class="gnw_media_caption">Kyle Fisher named Chief Financial Officer at Indianapolis-based Community Health Network</td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/adca27f7-0b71-4ccd-9241-1aa086b925cc/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/adca27f7-0b71-4ccd-9241-1aa086b925cc?size=2" ...</a></td></tr></table></td></tr></table></td></tr></table><p><a href=https://www.benzinga.com/pressreleases/18/06/g11916112/kyle-fisher-named-chief-financial-officer-for-community-health-network alt=Kyle Fisher named Chief Financial Officer for Community Health Network>Full story available on Benzinga.com</a></p> News Health Care Management Press Releases News Health Care Management Press Releases Benzinga Thu, 21 Jun 2018 16:22:05 +0000 Globe Newswire 11916112 at https://www.benzinga.com BAYCREST ANNOUNCES NEW BOARD CHAIR DALE H. LASTMAN, C.M. https://www.benzinga.com/pressreleases/18/06/g11916004/baycrest-announces-new-board-chair-dale-h-lastman-c-m <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Toronto, ON, June 21, 2018 (GLOBE NEWSWIRE) -- Baycrest and the Baycrest Foundation are pleased to announce the appointment of Mr. Dale H. Lastman, C.M. to the post of Chair of the Baycrest Board of Directors. </p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/fa8b85a4-dccf-4f65-ae0c-349282463bb6/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/fa8b85a4-dccf-4f65-ae0c-349282463bb6?size=2" border="0" width="300" height="300" alt="0_int_DaleHLastman.jpg" /></a></td> </tr> <tr> <td class="gnw_media_caption" width="5"></td> <td align="left" class="gnw_media_caption">Mr. Dale H. Lastman</td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d00ad530-8b31-4627-996b-6794bf28858d/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/d00ad530-8b31-4627-996b-6794bf28858d?size=2" border="0" width="300" height="167" alt="2_int_Capture.JPG" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p>Mr. Lastman is Chair of Goodmans LLP and practices corporate, commercial and securities law, providing counsel in connection with public offerings, mergers and acquisitions, and business restructurings.  He is a Director of Maple Leaf Sports &amp; Entertainment Ltd. and serves as an Alternate Governor for the NHL and NBA and a Governor of the Toronto Argonauts for the CFL. He also sits on the board of directors of RioCan Real Estate Investment Trust, Roots Ltd. and the CAMH Foundation.</p> <p>"Dale brings a wealth of knowledge and passion for Baycrest," says Dr. William Reichman, President &amp; CEO, Baycrest. "I look forward to the leadership he will bring to Baycrest as we work ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11916004/baycrest-announces-new-board-chair-dale-h-lastman-c-m alt=BAYCREST ANNOUNCES NEW BOARD CHAIR DALE H. LASTMAN, C.M.>Full story available on Benzinga.com</a></p> News Health Care Management Press Releases News Health Care Management Press Releases Benzinga Thu, 21 Jun 2018 16:03:43 +0000 Globe Newswire 11916004 at https://www.benzinga.com Becton Dickinson Positioned For Top-, Bottom-Line Outperformance, JPMorgan Says In Upgrade https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11914738/becton-dickinson-positioned-for-top-bottom-line-outperf <p><strong>Becton Dickinson and Co </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bdx#NYSE">BDX</a>) shares deserve to trade at a premium multiple to medical technology peers &mdash; even after accounting for the company&#39;s&nbsp;leverage &mdash;&nbsp;given the strength of its outlook over the next two to three&nbsp;years, according to JPMorgan.&nbsp;</p> <h3>The Analyst</h3> <p>Analyst Robbie Marcus upgraded&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/01/10993640/keybanc-initiates-becton-dickinson-and-co-with-bullish-">Becton Dickinson </a>from Neutral to Overweight and raised the price target from $250 to a December 2019 target of $275.&nbsp;</p> <h3>The Thesis</h3> <p>With <a href="https://www.bd.com/en-us/company/news-and-media/press-releases/dec-29-2017-bd-completes-bard-acquisition-creating-new-global-health-care-leader"> Bard </a> being assimilated into <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11496411/citi-projects-16-upside-for-becton-dickinson-in-upgrade?viewDesktop=1"> Becton Dickinson </a> for about two quarters now, the latter is likely to outperform the Street&#39;s top- and bottom-line expectations for the second half of 2018&nbsp;as well as fiscal 2019, Marcus said in a Thursday note.</p> <p>This will set up a &quot;beat-and raise scenario&quot; well ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11914738/becton-dickinson-positioned-for-top-bottom-line-outperf alt=Becton Dickinson Positioned For Top-, Bottom-Line Outperformance, JPMorgan Says In Upgrade>Full story available on Benzinga.com</a></p> Analyst Color BDX JPMorgan Robbie Marcus Upgrades Health Care Price Target Analyst Ratings General BDX US0758871091 Analyst Color Upgrades Health Care Price Target Analyst Ratings General Benzinga Thu, 21 Jun 2018 14:58:54 +0000 Shanthi Rexaline 11914738 at https://www.benzinga.com Has General Electric Hit Bottom? Cramer Says No https://www.benzinga.com/general/health-care/18/06/11914437/has-general-electric-hit-bottom-cramer-says-no <p><strong>General Electric Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ge#NYSE">GE</a>)&#39;s rough track record over the past few years turned worse this week when the Dow Jones Industrial Average booted the&nbsp;<a href="https://www.benzinga.com/stock/ge">company&#39;s stock</a>. With the stock trading at multiyear lows, the worst has to be over, right?</p> <p>Wrong, <a href="https://www.cnbc.com/2018/06/20/cramer-general-electrics-stock-doesnt-look-like-its-bottoming-yet.html">according to CNBC&#39;s Jim Cramer.</a></p> <h3>What Happened</h3> <p>Investors who think <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/18/06/11908422/why-ges-removal-from-the-dow-could-help-investors">GE&#39;s removal</a> from the coveted index is a positive need to ask themselves a simple question: &quot;on the basis of what?&quot;&nbsp;Cramer said during his daily &quot;Mad Money&quot; show Wednesday evening. Being removed from the index ...</p><p><a href=https://www.benzinga.com/general/health-care/18/06/11914437/has-general-electric-hit-bottom-cramer-says-no alt=Has General Electric Hit Bottom? Cramer Says No>Full story available on Benzinga.com</a></p> CNBC Dow Jones Industrial Average GE Jim Cramer Mad Money WBA Health Care Media General GE US3696041033 WBA Health Care Media General Benzinga Thu, 21 Jun 2018 14:12:39 +0000 Jayson Derrick 11914437 at https://www.benzinga.com NFL Alumni Partners with BEMER USA Marketing Affiliates https://www.benzinga.com/pressreleases/18/06/g11914826/nfl-alumni-partners-with-bemer-usa-marketing-affiliates <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Mount Laurel, NJ, June 21, 2018 (GLOBE NEWSWIRE) -- <b>NFL Alumni</b> announced today its partnership with <b>BEMER USA. </b>NFL Alumni is dedicated to upholding its responsibility to providing its members with the best possible benefits for their post NFL career which is why BEMER USA is a great addition to the team. BEMER USA&#039;s new medical technology that already services more than a million users worldwide will be available to NFL Alumni members.<br /><br />The BEMER technology (BEMER) is currently used by thousands of elite athletes and former athletes of all levels and is also being used in thousands of hospitals and clinics in tandem with other traditional medical services.  NASA has also signed a joint collaboration agreement with BEMER to pursue applications in space. This breakthrough technology can now be purchased by NFL Alumni members and their families for use in their own homes.</p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/b867579c-23b9-4144-9427-d2b1d43b7b2c/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/b867579c-23b9-4144-9427-d2b1d43b7b2c?size=2" border="0" width="300" height="73" alt="0_int_NFLAlumniBemerGroup.PNG" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p><br />How does it work?  The BEMER uses a patented electronic signal to improve blood flow in the smallest vessels of the body. This delivers many important benefits to users including significant improvements in:</p> <ul> <li>Nutrition and oxygen supply to cells       </li> <li>Cardiac function</li> <li>Sleep management</li> <li>Elimination of toxins</li> <li>Physical fitness and ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/18/06/g11914826/nfl-alumni-partners-with-bemer-usa-marketing-affiliates alt=NFL Alumni Partners with BEMER USA Marketing Affiliates>Full story available on Benzinga.com</a></p> Partnerships Health Care Sports Press Releases Health Care Sports Press Releases Benzinga Thu, 21 Jun 2018 14:00:00 +0000 Globe Newswire 11914826 at https://www.benzinga.com Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer https://www.benzinga.com/pressreleases/18/06/g11914825/sera-prognostics-appoints-dr-garrett-k-lam-as-chief-medical-officer <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">SALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8nn_T1Kk1aoLxxYnPlDvMh_Xn5RDUmheU-_gpjVgoKCsLiu-PQnQrOdpyJvP8ulJL7GzG20lb8lUuZO4kpUVkWXmzVBZeTXRwIu4x8F_1yw=" rel="nofollow" target="_blank" rel="nofollow">Sera Prognostics, Inc</a>., a women&#039;s healthcare company, announced today that Garrett K. Lam, M.D., FACOG, will be joining the company as chief medical officer on September 4, 2018.  Dr. Lam will direct all clinical development activities for Sera as the company achieves its vision to be The Pregnancy Company™.  He will lead a group of talented clinical operations professionals who support Sera&#039;s collaborations with research teams across the globe.<br /></p> <p align="left">"We are thrilled to have someone of Dr. Lam&#039;s stature and experience join Sera to continue to drive the company forward in improving the health and lives of women and infants," said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. "Garrett is highly respected for his expertise, his judgment and his commitment to patients.  His leadership will effect changes that positively transform pregnancy care worldwide."</p> <p align="left">As a maternal and fetal medicine/high risk pregnancy expert, Dr. Lam is currently professor of Obstetrics &amp; Gynecology, and Chairman of the Department of Obstetrics &amp; Gynecology at the University of Tennessee College of Medicine-Chattanooga.  He also serves as associate director of perinatal services for Regional Obstetrical Consultants in Chattanooga.  Dr. Lam received his medical degree from the University of Rochester and completed his obstetrics and gynecology residency at Good Samaritan Regional Medical Center in Phoenix.  He received his fellowship training in maternal fetal medicine at the University of North Carolina, Chapel Hill.  Dr. Lam has authored multiple book chapters and contributed to numerous peer reviewed articles in leading journals based on investigations of various clinical ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11914825/sera-prognostics-appoints-dr-garrett-k-lam-as-chief-medical-officer alt=Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 21 Jun 2018 14:00:00 +0000 Globe Newswire 11914825 at https://www.benzinga.com International Health Experts Take on Sodium https://www.benzinga.com/pressreleases/18/06/g11914364/international-health-experts-take-on-sodium <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Park City, Utah, June 21, 2018 (GLOBE NEWSWIRE) -- Four of the world&#039;s top scientists on cardiovascular health outcomes gathered today for a frank discussion on salt and health. They concluded that there is a dire need for large randomized controlled trials on the impact of salt on health outcomes before any population wide sodium reduction recommendation can be made. Held today at the at the 2018 World Salt Symposium, the panel included Dr. Michael H. Alderman, MD, Albert Einstein College of Medicine, Dr. Andrew Mente PhD, MA, McMaster University, David A. McCarron, MD, FACP, FAHA, University of California, Davis, and Professor Jan A. Staessen, MD, PhD, University of Leuven.</p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/b3b57703-b334-4c17-9195-f7e1efa597f1/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/b3b57703-b334-4c17-9195-f7e1efa597f1?size=2" border="0" width="300" height="283" alt="0_int_Saltlogoblack2.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p> </p> <p>Dr. Alderman, editor of the American Journal of Hypertension, said "Sodium consumption around the globe has a mean of about 3,600mg/day, and a range from 2,600 – 5,000mg/day. This mid-range describes about 90 percent of the world&#039;s population. More than 30 ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11914364/international-health-experts-take-on-sodium alt=International Health Experts Take on Sodium>Full story available on Benzinga.com</a></p> Goverment lifestyle Health Care Restaurants Press Releases General Health Care Restaurants Press Releases General Benzinga Thu, 21 Jun 2018 13:07:00 +0000 Globe Newswire 11914364 at https://www.benzinga.com Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for the Second Year in a Row https://www.benzinga.com/pressreleases/18/06/g11914094/flexion-therapeutics-named-one-of-boston-business-journals-best-places <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">BURLINGTON, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ" rel="nofollow">FLXN</a>) today announced that it has been named as one of the<em> Boston Business Journal&#039;s</em> "Best Places to Work" for the second year in a row. Flexion was ranked among the top 15 companies in the medium business category (100 to 249 employees). The awards were presented during a ceremony held at Symphony Hall in Boston on June 20.<br /></p> <p>The "Best Places to Work" program recognizes companies where voices are heard, cultures are thriving, and employees are engaged. In partnership with Quantum Workplace, the <em>Boston Business Journal</em> evaluates employers based on employees&#039; responses to survey questions focused around communication ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11914094/flexion-therapeutics-named-one-of-boston-business-journals-best-places alt=Flexion Therapeutics Named one of Boston Business Journal&#039;s Best Places to Work for the Second Year in a Row>Full story available on Benzinga.com</a></p> FLXN Health Care Press Releases FLXN Health Care Press Releases Benzinga Thu, 21 Jun 2018 12:59:56 +0000 Globe Newswire 11914094 at https://www.benzinga.com Emisphere Development Update https://www.benzinga.com/pressreleases/18/06/g11913867/emisphere-development-update <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>ROSELAND, N.J., June 21, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere Technologies, Inc.&#39;s (&#34;Emisphere&#34; or the &#34;Company&#34;) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EMIS#OTC" rel="nofollow">EMIS</a>) proprietary Eligen® Technology.<br /></p> <p>A copy of the Novo Nordisk&#39;s announcement can be found at:</p> <p><a href="https://www.globenewswire.com/Tracker?data=_hWXDdJOzNhwPaqjL336vJkT7DGxfjBfcTUgew8e8foQwZm-AnA4QBc5Qz9PsEy4GK0ZxJChPDoZ7UObtIkrNYNKerjgxZTZQUKXSh7XdxfPsAJt2qaXoVK2CxNdpLdYS9zHGsANd5asfxrHw9ryw5DF_mI-GC2V8PyDvYsV9A9TmyvmQsnhpDK8O6Hpf76a" rel="nofollow" target="_blank" rel="nofollow">https://www.novonordisk.com/media/news-details.2200408.html</a></p> <p><strong>About Emisphere </strong><br />Emisphere is ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11913867/emisphere-development-update alt=Emisphere Development Update>Full story available on Benzinga.com</a></p> EMIS Health Care Press Releases EMIS US2913451066 Health Care Press Releases Benzinga Thu, 21 Jun 2018 12:30:00 +0000 Globe Newswire 11913867 at https://www.benzinga.com Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD https://www.benzinga.com/pressreleases/18/06/g11913573/cynata-reports-positive-28-day-data-from-cohort-b-of-phase-1-trial-of- <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company&#039;s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD).<br /></p> <p align="justify"><strong><u>Key Highlights – Cohort B Day 28 Analysis</u></strong></p> <ul type="disc"> <li><strong>Overall Response rate by Day 28 was 86%</strong> (six out of seven patients treated with CYP-001 showed an improvement in the severity of GvHD by at least one grade compared to baseline)</li> <li><strong>Complete Response rate by Day 28 was 57% </strong>(GvHD signs/symptoms completely resolved in four out of seven patients treated with CYP-001)</li> <li><strong>Higher dose of CYP-001 administered in Cohort B elicited a faster response</strong> than the lower dose in Cohort A. By Day 28, Cohort A had a Complete Response rate of 12.5%, compared to 57% in Cohort B.</li> <li><strong>No treatment-related serious adverse events</strong> or safety concerns have been identified</li> <li><strong>All seven patients treated with CYP-001 survived at least until Day 28</strong></li> <li><strong>Data support advancement of CYP-001 into Phase 2 trial</strong></li> </ul> <p align="justify"><strong>Dr Ross Macdonald, Chief Executive Officer of Cynata, said: </strong><em>"The 28-day results for Cohort B are highly encouraging and, together with the excellent data from Cohort A, support the advancement of CYP-001 into a Phase 2 trial in GvHD.  Importantly, CYP-001&#039;s strong safety profile may enable us to advance the therapy directly into Phase 2 trials in other indications beyond GvHD where there is a high unmet medical need for a consistent and scalable source of high-quality MSCs. We are evaluating our options strategically and expect to provide more details at the appropriate time."</em></p> <p align="justify">Eight patients with steroid-resistant acute GvHD were enrolled in Cohort B, as originally planned.  Seven out of eight patients enrolled in Cohort B received two infusions of CYP-001 at a dose level of 2 million cells per kilogram of body weight, up to a maximum of 200 million cells per infusion. All treated patients have now reached the pre-specified Day 28 endpoint.</p> <p align="justify">As previously announced, the clinical investigator determined that one patient in Cohort B was no longer a suitable candidate for treatment, due to a medical complication that occurred shortly after enrolment but prior to treatment with CYP-001. This patient has been excluded from analysis, ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11913573/cynata-reports-positive-28-day-data-from-cohort-b-of-phase-1-trial-of- alt=Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD>Full story available on Benzinga.com</a></p> CYP.AX Health Care Press Releases General CYP.AX Health Care Press Releases General Benzinga Thu, 21 Jun 2018 12:00:00 +0000 Globe Newswire 11913573 at https://www.benzinga.com Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly https://www.benzinga.com/pressreleases/18/06/g11913262/crinetics-pharmaceuticals-awarded-up-to-3-2-million-in-sbir-grants-for <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it has been awarded up to approximately $3.2 million in Small Business Innovation Research (SBIR) grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to fund the continued research and development of its nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias (CHI) and acromegaly. Under award numbers R44DK115290 for CHI and R44DK088501 for acromegaly, Crinetics will be eligible to receive funding for up to approximately $1.9 million and $1.3 million, respectively.</p> <p>"We are pleased with the NIH&#039;s continuing support of our congenital hyperinsulinism and acromegaly programs," said Stephen Betz, Ph. D., Founder and Vice President of Biology of Crinetics. "These funds will help us progress CRN02481 for CHI and CRN00808 for acromegaly. Both of these rare diseases represent significant unmet medical needs, and ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11913262/crinetics-pharmaceuticals-awarded-up-to-3-2-million-in-sbir-grants-for alt=Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 21 Jun 2018 11:30:00 +0000 Globe Newswire 11913262 at https://www.benzinga.com Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index https://www.benzinga.com/pressreleases/18/06/g11913260/marinus-pharmaceuticals-to-be-added-to-the-russell-2000-and-russell-30 <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">Marinus&#039; addition to the indexes will be effective June 22, 2018, after market close</p> <p align="justify">RADNOR, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=sFmaD4OtF2vsB92oTYeKY1XyNycQ8I14I7j08HVKUxWct6vUPg3dPwxEhdmvpGqfxMsQmbrUTJ1rN8xSQg18ICFvqVpkwMT3j-VEeDJ_MmQ=" rel="nofollow" target="_blank" rel="nofollow">Marinus Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ" rel="nofollow">MRNS</a>) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it will be added to the Russell 2000<sup>®</sup> and Russell 3000<sup>®</sup> Indexes, effective Friday, June 22, 2018, after market close. </p> <p> "We are pleased with Marinus&#039; addition to the Russell indexes," said Christopher M. Cashman, Chief Executive Officer of Marinus. "We are committed to advancing the development of ganaxolone to improve the lives of children and mothers suffering from neuropsychiatric disorders and building shareholder value."</p> <p><strong>About FTSE Russell</strong><br /> Russell US Indexes are the leading US equity benchmarks for institutional investors. This broad range of US indexes allow investors to track current and historical market performance by specific size, investment style and other market characteristics. All Russell US Indexes are subsets of the Russell 3000<sup>®</sup> Index, which includes the well-known large cap Russell 1000<sup>®</sup> Index and small cap Russell 2000<sup>®</sup> Index. The Russell US Indexes are designed as the building blocks of a broad range of financial products, such as index tracking funds, derivatives and Exchange Traded Funds (ETFs), as well as being performance benchmarks.<br />For more information on the FTSE Russell, go to the <a href="https://www.globenewswire.com/Tracker?data=F7MTwAzbeKC0X6250665_PWKgNf64FwLS_4u8gCbIMQt2x2RyxvVGkZWKKZ4IWZsC_tll_6063jKdhjqShoRNoz4GNft6JMJtVdt5vZ6KhsCiywG99t0rzmCbBGnd7rnzBiIGp9ZoR7A_E993Nvv18thwcAW73Fpm7YPGISqKo6f9-oJH5E9IKVYg44rCrHajKOLRn-9q_79H7OQ-DC6LCs9dv0GbBzH6KwNBWsS9jAyI9hZ7qrtucxbIRZ1Ab7WiJEec5Wk1kjZXu5P9qmfqmx9Sph3DBx_G4Tz8OHQgnHI4vkF445lKcznaDxJxkKwquOH0lulb4c6VaA6zCg9TK7Kh8lP14Irrm-z7ntitmiZmDX0gPLotOmET_AezQ3hnOzb9GlICcq2LcF1qhvxUvCREpGqX8jz_vkpWfT7vCaYlpI042AOQaICFsyiEPio4ICBf9ZPucOgLf7dbVF1SzM3vdYzZzUJloVqZkFFCHtBS3E0-lkoadEO1FUE9MlTPrjPDNY4fhTUP5o0GFJued1uo0xWxG65xB22nfAWZYMOoB2sAFiV4f8EDtwfqJ9rPgmRfmnAaphzRaKBYZvQGoS_SScwqRTcvL61MLbr7-Q_FtkXrQy1zHF4yxZCvIMnBHliF4o8FhvvwB1BfgGenQ==" rel="nofollow" target="_blank" rel="nofollow">FTSE Russell website</a>.</p> <p ...<p><a href=https://www.benzinga.com/pressreleases/18/06/g11913260/marinus-pharmaceuticals-to-be-added-to-the-russell-2000-and-russell-30 alt=Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index>Full story available on Benzinga.com</a></p> MRNS Health Care Press Releases MRNS Health Care Press Releases Benzinga Thu, 21 Jun 2018 11:30:00 +0000 Globe Newswire 11913260 at https://www.benzinga.com